my.bionity.com
With an accout for my.bionity.com you can always see everything at a glance – and you can configure your own website and individual newsletter.
The Alpine Institute for Drug Discovery is a Switzerland-based company aiming at creating shared value for the community by maintaining industrial know-how in today’s changing pharmaceutical landscape. AiDD’s mission is to maximise the socio-economical impact of academic discoveries by performing tr more
Amal Therapeutics SA is a privately held Swiss biotech start-up company and a spin-off from the University of Geneva. Amal was incorporated on September 3rd 2012 and secured seed funding in February 2014 to establish and validate its technology platform. Boehringer Ingelheim Venture Fund led this in more
QIAGEN N.V. announced it has entered into an agreement to acquire N-of-One, Inc., a privately-held U.S. molecular decision support company and pioneer in clinical interpretation services for complex genomic data. The addition of N-of-One will enable QIAGEN to significantly expand its decision-suppor more
Purdue University researchers have developed a technology aimed at making it easier to deliver cancer treatment to the right "address" in the body while also easing the painful side effects of chemotherapy on patients. One of the big issues with chemotherapy is that most treatment approaches focus o more
In an article Medical University of South Carolina investigators report that a new compound enhances the efficacy of proteasome inhibitors (PIs), the standard-of-care for the treatment of multiple myeloma (MM), in cell culture and in preclinical models. The efficacy and safety of the novel combinati more
Immunoassays are bioanalytical methods based on antibodies. These include ELISA, EIA, RIA, Western blotting, protein arrays, lateral flow assays, more
The conference agenda will focus on new translational advances in the treatment of cancer as well as provide updates of conventional therapies for a number of the most common tumor types. The meeting objectives are designed to introduce the audience to the latest information on targeted therapies,
927 million. That’s how many lives our products touched in 2018. And while we’re proud of that fact, in this world of digital and technological transformation, we must also ask ourselves this: how can we continue to improve and extend even more people’s lives? We believe the answers are found when c more
by Lisa Jane Mackenzie, Mariko Leanne Carey, Eiji Suzuki, Robert William Sanson-Fisher, Hiromi Asada, Masakazu Ogura, Catherine D’Este, Michio Yoshimura, Masakazu Toi This study assessed agreement between radiation oncologist- and cancer patient-reported perceptions about cancer diagnosis, time s more
We examined the impact of race on the maximum tolerated doses (MTD) and final approved doses (FAD) of single-agent molecular-targeted agents (MTA) in North America/Europe (NA/EU) and Asia. We searched PubMed and regulatory databases to identify targeted drugs approved globally and compared their FAD more
Artificial intelligence (AI) algorithms, particularly deep learning, have demonstrated remarkable progress in image-recognition tasks. Methods ranging from convolutional neural networks to variational autoencoders have found myriad applications in the medical image analysis field, propelling it forw more
Introduction GlobalData's “Partnerships, Licensing, Investments and M&A Deals and Trends in Pharmaceuticals - February 2012” report is an essential source of data and trend analysis on partnerships, licensing, mergers and acquisitions (M&As) and financings in the pharmaceuticals industry. The repor more
IDL Biotech AB (IDL Biotech AB) is a Sweden based biotechnology company engaged in developing, manufacturing and marketing of in vitro diagnostics within the areas of oncology and bacteriology. The product pipeline of the company consists of TPS, TPAcyk, MonoTotal and UBC, which are cytokeratin tumo more
BMI View: Uzbekistan’s pharmaceutical market remains one of the fastest growing in the Central and Eastern Europe (CEE) region and its population and currently low levels of per capita pharmaceutical spending gives it the greatest long-term growth potential of any Central Asian market. BMI forecasts more
Watchlist
This is where you can add this topic to your personal favourites
© 1997-2019 LUMITOS AG, All rights reserved
